Výsledky vyhledávání - "Sridharan, Nithya"

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Effectiveness and tolerability of nimotuzumab in unresectable, locally advanced/metastatic esophageal cancer: Indian hospital-based retrospective evidence

Autor: Subramanian, Sundaram, Sridharan, Nithya, Balasundaram, V., Chaudhari, Sameer

Publikováno v: South Asian Journal of Cancer, Vol 8, Iss 2, Pp 112-115 (2019)
South Asian Journal of Cancer

Context: Epidermal growth factor receptor (EGFR) is overly expressed in esophageal squamous cell carcinoma (ESCC) and is important prognostic and predictive biomarker. Nimotuzumab is a humanized anti-EGFR monoclonal antibody and has documented promis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::881a5f0ee8a43e9b98114cac0fcff80e
http://journal.sajc.org/article.asp?issn=2278-330X

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Nimotuzumab with Induction Chemotherapy and Chemo-Radiation in Patients with Advanced Head and Neck Cancer

Autor: Sundaram Subramanium, Poojar Kiran, Sridharan Nithya, Venkatanarayan Balasundaram

Publikováno v: Journal of Cancer Therapy. :146-152

Background: Head and neck squamous cell carcinoma (HNSCC), is a common malignancy in the Indian Population. In locally advanced disease, chemoradiation is the standard of care. Although induction chemotherapy has been much studied, no clear benefit h

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::349bc78e0bfb83e951bb2c099ac0256e
https://doi.org/10.4236/jct.2015.62016

Zobrazit plný text záznamu

Long term efficacy and safety of nimotuzumab in unresectable locally advanced squamous cell carcinoma of head and neck: A real world Indian experience

Autor: Sameer Chaudhari, Sundaram Subramanian, Sridharan Nithya

Publikováno v: Journal of Clinical Oncology. 36:e18077-e18077

e18077Background: Nimotuzumab is an anti-EGFR monoclonal antibody approved for the treatment of head and neck cancer (HNC) in India and 20 other countries. However, available evidence on long term ...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::78d32caa7f78d10d8e576a6c607064c6
https://doi.org/10.1200/jco.2018.36.15_suppl.e18077

Zobrazit plný text záznamu

Tumour response and survival of treatment-naïve head and neck cancer patients treated with nimotuzumab: A systematic review and meta-analysis

Autor: Shyam Ji Rawat, Sridharan Nithya, Naresh Somani, Sundaram Subramanian, Sameer Chaudhari, Ashwani Marwah

Publikováno v: Journal of Clinical Oncology. 36:e18083-e18083

e18083Background: Several trials have studied the efficacy of Nimotuzumab in head and neck cancer. However, they are limited by small sample size and varying results. The purpose of this meta-analy...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7422f49f1761fe7728920e474c52123d
https://doi.org/10.1200/jco.2018.36.15_suppl.e18083

Zobrazit plný text záznamu

Periodical

Efficacy and safety of nimotuzumab in unresectable, recurrent, and/or metastatic squamous cell carcinoma of the head and neck: A hospital-based retrospective evidence

Autor: Subramanian, Sundaram, Sridharan, Nithya, Balasundaram, V., Chaudhari, Sameer

Publikováno v: South Asian Journal of Cancer; July 2018, Vol. 7 Issue: 3 p188-192, 5p

Zobrazit plný text záznamu

Periodical

Oncology gold standard® practical consensus recommendations for the use of monoclonal antibodies in the management of squamous cell carcinoma of head and neck

Autor: Babu, Govind, Bahl, Ankur, Bhattacharya, G. S., Bhowmik, K. T., Dattatraya, P. S., Ghadyalpatil, Nikhil, Karandikar, S. M., Kulkarni, Padmaj, Sridharan, Nithya, Parikh, Purvish, Prabhash, Kumar, Raja, T., Rajasundaram, S., Subramanian, S., Talapatra, Kaustav, Vaid, Ashok

Publikováno v: South Asian Journal of Cancer; October 2017, Vol. 6 Issue: 4 p154-160, 7p

Zobrazit plný text záznamu

Akademický článek

Oncology Gold Standard ^® practical consensus recommendations for the use of monoclonal antibodies in the management of squamous cell carcinoma of head and neck.

Autor: Babu G; Department of Medical Oncology, Kidwai Memorial Institute of Oncology, Bengaluru, Karnataka, India., Bahl A; Department of Medical Oncology, Max Hospital, New Delhi, India., Bhattacharya GS; Department of Medical Oncology, Fortis Hospital, Kolkata, West Bengal, India., Bhowmik KT; Department of Radiation Oncology, Safdarjung Hospital, New Delhi, India., Dattatraya PS; Department of Medical Oncology, Omega Hospital, Hyderabad, Telangana, India., Ghadyalpatil N; Department of Medical Oncology, Yashoda Hospitals, Hyderabad, Telangana, India., Karandikar SM; Department of Medical Oncology, Ruby Hall Clinic, Pune, Maharashtra, India., Kulkarni P; Department of Medical Oncology, Deenanath Mangeshkar Hospital, Pune, Maharashtra, India., Sridharan N; Department of Medical Oncology, VS Hospital, Chennai, Tamil Nadu, India., Parikh P; Department of Precision Oncology, Asian Cancer Institute, Mumbai, Maharashtra, India., Prabhash K; Department of Medical Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India., Raja T; Department of Medical Oncology, Apollo Speciality Hospital, Chennai, Tamil Nadu, India., Rajasundaram S; Department of Surgical Oncology, Global Institute of Oncology, Chennai, Tamil Nadu, India., Subramanian S; Department of Medical Oncology, VS Hospital, Chennai, Tamil Nadu, India., Talapatra K; Department of Radiation Oncology, KDA Hospital, Mumbai, Maharashtra, India., Vaid A; Department of Medical Oncology, Medanta Hospital, Gurugram, Haryana, India.

Publikováno v: South Asian journal of cancer [South Asian J Cancer] 2017 Oct-Dec; Vol. 6 (4), pp. 154-160.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání